RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

39.41+0.42 (+1.08%)Market Closed

Market Summary

39.41+0.42

Market Closed

1.08%

RVMD Alerts

2 major insider sales recently.

RVMD Stock Price

View Fullscreen

RVMD RSI Chart

RVMD Valuation

Market Cap

6.5B

Price/Earnings (Trailing)

-13.44

Price/Sales (Trailing)

562.06

EV/EBITDA

-12.89

Price/Free Cashflow

-14.21

RVMD Price/Sales (Trailing)

RVMD Profitability

EBT Margin

-4212.40%

Return on Equity

-28.07%

Return on Assets

-25.38%

Free Cashflow Yield

-7.03%

RVMD Fundamentals

RVMD Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

-95.16%

Rev. Growth (Qtr)

-100%

RVMD Earnings

Earnings (TTM)

-484.3M

Earnings Growth (Yr)

-70.35%

Earnings Growth (Qtr)

28.19%

Breaking Down RVMD Revenue

Last 7 days

5.9%

Last 30 days

7.1%

Last 90 days

33.7%

Trailing 12 Months

55.4%

How does RVMD drawdown profile look like?

RVMD Financial Health

Current Ratio

18.45

RVMD Investor Care

Shares Dilution (1Y)

55.19%

Diluted EPS (TTM)

-3.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	34.8M	29.5M	26.2M	11.6M
2022	26.8M	27.3M	29.5M	35.4M
2021	41.6M	40.2M	28.7M	29.4M
2020	48.4M	46.2M	46.3M	43.0M
2019	27.6M	35.1M	42.6M	50.0M
2018	0	0	0	20.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of REVOLUTION Medicines Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	anders jack	acquired	26,800	2.68	10,000	chief financial officer
May 03, 2024	anders jack	sold	-400,260	40.026	-10,000	chief financial officer
Apr 10, 2024	patel sushil	acquired	36,204	16.8	2,155	-
Apr 10, 2024	patel sushil	sold	-79,735	37.00	-2,155	-
Apr 10, 2024	goldsmith mark a	sold	-266,122	35.4829	-7,500	see remarks
Apr 10, 2024	goldsmith mark a	sold	-353,346	35.3345	-10,000	see remarks
Mar 27, 2024	cislini jeff	sold	-46,481	30.9873	-1,500	general counsel
Mar 18, 2024	kelsey stephen michael	sold	-67,051	31.5832	-2,123	see remarks
Mar 18, 2024	cislini jeff	sold	-39,542	31.5832	-1,252	general counsel
Mar 18, 2024	horn margaret a	sold	-92,033	31.5832	-2,914	chief operating officer

Which funds bought or sold RVMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	reduced	-22.25	-6,139,940	42,500,100	1.08%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-7.65	123,641	3,396,170	-%
May 16, 2024	Mubadala Investment Co PJSC	unchanged	-	986,900	8,959,940	0.04%
May 16, 2024	COMERICA BANK	new	-	18,159	18,159	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-34.02	-1,455,210	4,172,720	-%
May 15, 2024	Avidity Partners Management LP	added	958	18,745,200	20,466,000	0.66%
May 15, 2024	Column Group LLC	unchanged	-	164	1,483	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	77.87	62,975,200	126,067,000	0.07%
May 15, 2024	CAROLINAS WEALTH CONSULTING LLC	sold off	-100	-29,340	-	-%
May 15, 2024	Logos Global Management LP	sold off	-100	-10,038,000	-	-%

Are Funds Buying or Selling RVMD?

Are funds buying RVMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVMD

No. of Funds

RVMD Alerts

2 major insider sales recently.

Unveiling REVOLUTION Medicines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	1.9%	3,079,232	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0.1%	132,579	SC 13G/A
Feb 13, 2024	bb biotech ag	3.1%	5,046,700	SC 13G/A
Feb 13, 2024	vanguard group inc	8.93%	14,634,391	SC 13G/A
Feb 12, 2024	farallon capital partners, l.p.	0.2%	329,602	SC 13G/A
Feb 09, 2024	column group iii, lp	0%	0	SC 13G/A
Feb 08, 2024	wellington management group llp	9.09%	14,882,086	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	12,954,314	SC 13G/A
Nov 09, 2023	farallon capital partners, l.p.	0.3%	291,600	SC 13G
Nov 09, 2023	wellington management group llp	12.99%	14,219,430	SC 13G/A

Recent SEC filings of REVOLUTION Medicines Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	S-3ASR	S-3ASR
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	4	Insider Trading
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to REVOLUTION Medicines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

REVOLUTION Medicines Inc News

Latest updates

REVOLUTION Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	742,000	-	3,824,000	7,014,000	15,330,000	3,356,000	9,116,000	7,578,000	9,460,000	1,101,000	8,698,000	10,131,000	8,751,000	12,661,000	10,025,000	11,546,000	12,088,000	12,506,000	12,281,000	13,166,000
Operating Expenses	-22.1%	140,859,000	180,725,000	123,248,000	112,621,000	82,171,000	77,037,500	79,889,000	71,205,000	65,527,000	62,373,000	54,264,000	53,233,000	47,528,000	42,831,000	40,212,000	38,009,000	32,628,000	31,652,000	26,065,000	22,842,000	23,602,000
S&GA Expenses	-100.0%	-	32,244,000	15,513,000	14,640,000	13,224,000	10,910,500	10,434,000	10,204,000	9,037,000	8,692,000	7,791,000	7,297,000	6,670,000	5,825,000	5,341,000	5,091,000	5,171,000	4,162,000	3,103,000	2,725,000	2,416,000
R&D Expenses	-20.5%	118,021,000	148,481,000	107,735,000	97,981,000	68,947,000	66,127,000	69,455,000	61,001,000	56,490,000	53,681,000	46,473,000	45,936,000	40,858,000	37,006,000	34,871,000	32,918,000	27,457,000	27,490,000	22,962,000	20,117,000	21,186,000
EBITDA Margin	-11.0%	-41.69	-37.55	-12.63	-9.89	-7.33	-6.93	-8.18	-8.11	-7.61	-6.26	-5.76	-3.47	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	12,000	14,000	17,000	19,000	21,000	-	-	-	-
Income Taxes	-100.0%	-	343,000	-3,867,000	-	-	-123,000	-297,000	-	-	-	-	-	-	362,000	-	-58,000	-675,000	-	-	-	-
Earnings Before Taxes	28.0%	-116,003,000	-161,194,000	-112,301,000	-98,298,000	-68,098,000	-56,630,000	-73,626,000	-61,222,000	-57,647,000	-52,676,000	-52,940,000	-44,299,000	-37,176,000	-33,842,000	-27,221,000	-27,273,000	-20,194,000	-18,969,000	-12,818,000	-10,119,000	-10,131,000
EBT Margin	-10.9%	-42.12	-37.99	-12.81	-10.05	-7.46	-7.04	-8.31	-8.24	-7.73	-6.37	-5.87	-3.54	-	-	-	-	-	-	-	-	-
Net Income	28.2%	-116,003,000	-161,537,000	-108,434,000	-98,298,000	-68,098,000	-56,507,000	-73,329,000	-61,222,000	-57,647,000	-52,676,000	-52,940,000	-44,299,000	-37,176,000	-34,204,000	-27,221,000	-27,215,000	-19,519,000	-14,596,000	-12,818,000	-10,119,000	-10,131,000
Net Income Margin	-11.0%	-41.82	-37.68	-12.66	-10.03	-7.44	-7.03	-8.30	-8.24	-7.73	-6.37	-5.88	-3.55	-	-	-	-	-	-	-	-	-
Free Cashflow	-33.2%	-163,727,000	-122,880,000	-103,032,000	-68,240,000	-64,149,000	-64,664,000	-55,262,000	-58,242,000	-57,049,000	-40,448,000	-37,042,000	-35,393,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-7.4%	1,908	2,062	984	1,074	1,073	812	826	633	683	738	735	774	812	567	595	454	454	221
Current Assets	-8.0%	1,729	1,879	824	922	923	660	675	483	534	590	624	661	697	454	483	340	362	134
Cash Equivalents	-58.6%	288	696	358	380	427	161	179	106	98.00	108	129	196	352	104	65.00	24.00	183	17.00
Net PPE	3.6%	24.00	23.00	20.00	20.00	19.00	19.00	18.00	16.00	13.00	12.00	10.00	11.00	11.00	9.00	7.00	7.00	7.00	7.00
Goodwill	0%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
Liabilities	-22.3%	183	236	147	143	121	127	144	134	132	135	97.00	89.00	89.00	93.00	90.00	93.00	69.00	68.00
Current Liabilities	-34.8%	94.00	144	86.00	78.00	55.00	62.00	73.00	64.00	57.00	60.00	52.00	46.00	44.00	47.00	42.00	44.00	42.00	43.00
Shareholder's Equity	-5.5%	1,725	1,826	837	931	952	685	681	499	551	603	638	685	723	475	505	360	385	-
Retained Earnings	-14.3%	-1,300	-1,137	-976	-867	-769	-701	-644	-571	-510	-452	-400	-347	-302	-265	-231	-204	-176	-157
Additional Paid-In Capital	0.6%	2,980	2,963	1,814	1,800	1,722	1,388	1,329	1,072	1,063	1,056	1,038	1,032	1,025	740	736	564	562	5.00
Shares Outstanding	0.1%	165	165	109	109	106	90.00	85.00	74.00	74.00	73.00	72.00	73.00	-	-	-	-	-	-
Float	-	-	-	-	2,757	-	-	-	1,231	-	-	-	1,956	-	-	-	1,107	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-33.2%	-160	-120	-100	-67.12	-62.39	-61.79	-51.74	-55.72	-55.16	-39.26	-36.59	-34.08	-37.25	-25.03	-27.02	-19.99	-28.02	-11.65	-13.86	-11.50	-12.60
Share Based Compensation	-36.3%	16.00	25.00	14.00	13.00	10.00	8.00	8.00	8.00	7.00	6.00	6.00	5.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	0.00
Cashflow From Investing	34.8%	-247	-380	77.00	-43.54	4.00	-7.10	-123	62.00	44.00	9.00	-30.18	-122	2.00	63.00	-100	-136	-59.72	8.00	-59.80	-55.95	6.00
Cashflow From Financing	-99.9%	1.00	839	1.00	65.00	324	51.00	248	1.00	0.00	11.00	0.00	1.00	282	1.00	169	-1.34	254	-1.53	10.00	90.00	0.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RVMD Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 0	$ 7,014
Revenue, Product and Service [Extensible Enumeration]	Collaboration Revenue Member	Collaboration Revenue Member
Operating expenses:
Research and development	$ 118,021	$ 68,947
General and administrative	22,838	13,224
Total operating expenses	140,859	82,171
Loss from operations	(140,859)	(75,157)
Other income, net:
Interest income	23,760	7,059
Other expense, net	(2,809)	0
Change in fair value of warrant liabilities and contingent earn-out shares	3,905	0
Total other income, net	24,856	7,059
Loss before income taxes	(116,003)	(68,098)
Benefit from income taxes	0	0
Net loss	$ (116,003)	$ (68,098)
Net loss per share attributable to common stockholders, basic	$ (0.7)	$ (0.72)
Net loss per share attributable to common stockholders, diluted	$ (0.7)	$ (0.72)
Weighted-average common shares used to compute net loss per share, basic	164,729,200	94,831,979
Weighted-average common shares used to compute net loss per share, diluted	164,729,200	94,831,979
Comprehensive loss:
Net Income (Loss)	$ (116,003)	$ (68,098)
Other comprehensive gain (loss):
Unrealized gain (loss) on investments, net	(1,742)	1,224
Comprehensive loss	$ (117,745)	$ (66,874)

RVMD Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 288,432	$ 696,148
Marketable securities	1,415,108	1,156,807
Accounts receivable	0	1,254
Prepaid expenses and other current assets	25,662	25,072
Total current assets	1,729,202	1,879,281
Property and equipment, net	23,697	22,865
Operating lease right-of-use asset	76,193	77,149
Intangible assets, net	57,472	57,739
Goodwill	14,608	14,608
Restricted cash	3,031	3,031
Other noncurrent assets	4,159	7,032
Total assets	1,908,362	2,061,705
Current liabilities:
Accounts payable	32,379	61,788
Accrued expenses and other current liabilities	53,175	74,694
Operating lease liability, current	8,169	7,369
Total current liabilities	93,723	143,851
Deferred tax liability	3,115	3,115
Operating lease liability, noncurrent	79,860	80,575
Warrant liabilities	3,157	6,512
Other noncurrent liabilities	3,040	1,458
Total liabilities	182,895	235,511
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; none issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 170,473,067 and 170,234,594 shares issued as of March 31, 2024 and December 31, 2023, respectively; 164,913,014 and 164,674,594 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	16	16
Additional paid-in capital	2,980,360	2,963,342
Accumulated other comprehensive income (loss)	(1,198)	544
Accumulated deficit	(1,253,711)	(1,137,708)
Total stockholders' equity	1,725,467	1,826,194
Total liabilities and stockholders' equity	$ 1,908,362	$ 2,061,705

About REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CEO	Dr. Mark A. Goldsmith Ph.D.
WEBSITE	revmed.com
INDUSTRY	Biotechnology
EMPLOYEES	292

REVOLUTION Medicines Inc Frequently Asked Questions

What is the ticker symbol for REVOLUTION Medicines Inc? What does RVMD stand for in stocks?

RVMD is the stock ticker symbol of REVOLUTION Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REVOLUTION Medicines Inc (RVMD)?

As of Fri May 17 2024, market cap of REVOLUTION Medicines Inc is 6.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers. The fair value of REVOLUTION Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of REVOLUTION Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is REVOLUTION Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether RVMD is over valued or under valued. Whether REVOLUTION Medicines Inc is cheap or expensive depends on the assumptions which impact REVOLUTION Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVMD.

What is REVOLUTION Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RVMD's PE ratio (Price to Earnings) is -13.44 and Price to Sales (PS) ratio is 562.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVMD PE ratio will change depending on the future growth rate expectations of investors.